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esponsibility of Xi'aAbstract A simple, sensitive and high throughput ultra performance liquid chromatography tandem
mass spectrometry method has been developed for the determination of mycophenolic acid in human
plasma. The method involved simple protein precipitation of MPA along with its deuterated analog as an
internal standard (IS) from 50 mL of human plasma. The chromatographic analysis was done on Acquity
UPLC C18 (100 mm 2.1 mm, 1.7 mm) column under isocratic conditions using acetonitrile and 10 mM
ammonium formate, pH 3.00 (75:25, v/v) as the mobile phase. A triple quadrupole mass spectrometer
operating in the positive ionization mode was used for quantitation. In-source conversion of mycophenolic
glucuronide metabolite to the parent drug was selectively controlled by suitable optimization of cone
voltage, cone gas ﬂow and desolvation temperature. The method was validated over a wide concentration
range of 15–15000 ng/mL. The mean extraction recovery for the analyte and IS was495%. Matrix effect
expressed as matrix factors ranged from 0.97 to 1.02. The method was successfully applied to support a
bioequivalence study of 500 mg mycophenolate mofetil tablet in 72 healthy subjects.
& 2013 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.sity. Production and hosting by Elsev
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Mycophenolic acid (MPA) is the active metabolite of ester prodrug
mycophenolate mofetil (MPM) and is widely used as an immu-
nosuppressant drug to prevent the rejection of organ transplanta-
tion and in the treatment of autoimmune disease [1,2]. To improve
its oral bioavailability MPA is administered as MPM, which is
completely absorbed and rapidly hydrolyzed by esterases to MPA.
It is a selective, reversible and non-competitive inhibitor of inosineier B.V. All rights reserved.
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the de novo synthesis of guanosine nucleotides [3]. MPA is primarily
metabolized by uridine diphosphate glucuronosyl enzyme in the liver,
kidney and intestine to phenolic mycophenolic acid glucuronide
(MPAG) metabolite which is recovered in urine. MPAG is pharma-
cologically inactive and can hydrolyze back to MPA by β-glucur-
onidase during entrohepatic recirculation [4,5]. This leads to a second
concomitant peak in the plasma concentration-time proﬁle between
6–12 h after administration and might contribute to the gastrointest-
inal toxicity [6]. Additionally, MPA is further metabolized to two
minor metabolites namely acyl glucuronide (AcMPAG) and phenolic
glucoside of MPA. MPA is highly bound to plasma proteins, mainly
to human serum albumin (97–99%) [7]. Clinical pharmacokinetics of
MPA reveal signiﬁcant inter and intra subject variation in plasma
concentration [8], which can be associated with different factors such
as renal allograft function, hepatic function, MPA unbound fraction,
entrohepatic recirculation, and concomitant immunosuppressant ther-
apy [9]. Hence therapeutic drug monitoring for MPA is necessary to
optimize outcomes, especially in patients with high rejection risk [10].
Moreover, due to low therapeutic levels it is essential to develop
sensitive, rugged and rapid bioanalytical methods for its determination
in biological ﬂuids to minimize the risk of drug accumulation, and for
optimization of therapy to reduce the frequency of adverse effects.Table 1 Comparative summary of liquid chromatographic methods
in plasma.
Sr.
no.
Detection
technique
Human
plasma
volume
(mL)
Extraction procedure; internal
standard
Recov
(%)
1a LC–MS/MS 100 PP with perchloric acid and
sodium tungstate; carboxy
butoxy ether of MPA
91–11
2a LC–MS/MS 100 SPE on Phenomenex Strata-X
cartridges; indomethacin
82–92
3a LC–MS/MS 100 PP with acetonitrile and formic
acid; carboxy butoxy ether of
MPA
98.5–
101.7
4a LC–MS/MS 100 LLE with diethyl ether at pH
4.0; PPA
43.3–6
5a LC–MS/MS 10 Ultraﬁltration followed by on-
line SPE; mycophenolic acid-
d3
89.3–9
6 LC–MS/MS 50 SPE on Waters MAX Oasis
plates; MPA cyclopropane
analog
81.3–8
7 LC–MS/MS 250 LLE; pioglitazone –
8a LC–MS/MS 20 PP with acetonitrile;
[13C, 2H3]–MPA
82.0
9a UPLC–MS/MS 10 PP with acetonitrile; PPA 78.1–
129.7
10a UPLC–MS/MS 50 PP with acetonitrile;
mycophenolic acid-d3
–
11 UPLC–MS/MS 50 PP with acetonitrile;
mycophenolic acid-d3
96.8–
101.1
aAlong with metabolites; MPA: mycophenolic acid; MPM: mycophenola
liquid-liquid extraction; PPA: N-phthaloyl-L-phenylalanine; EMIT: enzymeSeveral methods have been reported for the analysis of MPA
and its metabolites in different biological ﬂuids by electrophoresis
[11–14], immunoassay technique [15–17], high performance
liquid chromatography using diode array [18], ﬂuorescence [19–
21], UV [22–29], and mass spectrometry detection [30–41].
Relatively few UPLC–MS/MS based methods are available in
literature for rapid analysis of MPA in biological samples [42,43].
Kuhn et al. [42] have developed a rapid method to determine MPA
and MPAG with a limit of quantitation (LOQ) of 50 ng/mL and
2300 ng/mL respectively in serum and plasma. A comparable
method with LOQ of 100 ng/mL for MPA was used for a
pharmacokinetic study in kidney transplant recipients [43]. A
summary of salient features of liquid chromatographic methods
with mass spectrometry detection for determination of total MPA
concentration in human plasma is presented in Table 1.
Ultra performance liquid chromatography (UPLC) is an ideal
tool for rapid separation of complex mixtures in both isocratic and
gradient modes. Improved separation efﬁciency and a decrease in
the analysis time can be realized by reducing the particle size of
the column packing material. The advantage of UPLC over
conventional HPLC is the ability to increase the speed without
sacriﬁcing efﬁciency [44]. In the present work, a simple, sensitive,
selective and rapid UPLC–MS/MS method has been developedwith mass detection developed for determination of total MPA
ery Linear
range
(ng/mL)
Run
time
(min)
Application Ref.
0 100–
50000
4.0 – [31]
50–
50000
7.0 Pharmacokinetic study with 1.5 g
MPM in 52 healthy volunteers
[33]
50–
30000
4.0 Pharmacokinetic study with MPM in
healthy volunteers and patients
[35]
0.0 50–
100000
3.0 Method comparison with
commercially available EMIT
[36]
9.1 100–
40000
2.0 Analysis in dried blood/plasma spots [37]
4.7 19.95–
19955
– Bioequivalence study with 500 mg
MPM in 103 healthy subjects
[38]
75.43–
24965
4.0 Bioequivalence study with 500 mg
MPM in 117 healthy subjects
[39]
80–
20000
2.0 Pharmacokinetic study with 500 mg
MPM twice daily in a renal pediatric
patient
[40]
50–
1000000
2.0 Analysis of 121 heart transplantation
patients who used MPM as part of
multiple-drug regime
[42]
100–
20000
2.0 Analysis of clinical samples collected
from 15 de novo kidney transplant
recipients
[43]
15–
15000
2.0 Bioequivalence study with 500 mg
MPM in 72 healthy subjects
PM
te mofetil; PP: protein precipitation; SPE: solid phase extraction; LLE:
multiplied immunoassay technique; PM: present method.
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plasma samples. Potential interference due to in-source conversion
of its principal metabolite MPAG to MPA was suitably controlled
through optimized mass parameters. The method requires only
50 mL human plasma for sample processing and demonstrates
excellent performance in terms of ruggedness and efﬁciency
(2.0 min). It was successfully applied to support a pivotal
bioequivalence study in 72 healthy subjects.2. Experimental
2.1. Chemicals and materials
Reference standards of mycophenolic acid (MPA, 98%), myco-
phenolic acid-d3 [MPA-d3 as an internal standard (IS), 98%], and
phenyl glucuronide of mycophenolic acid (MPAG, 98%) were
obtained from Toronto Research Chemicals (Toronto, Canada).
HPLC grade acetonitrile was procured from Merck (Darmstadt,
Germany). Formic acid and ammonium formate were purchased
from Spectrochem Pvt. Ltd. (Mumbai, India), and Sigma-Aldrich
(St. Louis, MO, USA) respectively. Puriﬁed water was obtained
from a Milli-Q water puriﬁcation system from Millipore (Banga-
lore, India). Blank human plasma was obtained from in-house
clinical department and was stored at −20 1C until use.
2.2. Liquid chromatographic and mass spectrometric conditions
A Waters Acquity UPLC system (MA, USA) consisting of binary
solvent manager, sample manager and column manager was used
for setting the reverse-phase liquid chromatographic conditions.
The analysis of MPA and IS was performed on Waters Acquity
UPLC BEH C18 (100 mm 2.1 mm, 1.7 mm) column maintained
at 40 1C. The mobile phase consisted of acetonitrile and 10 mM
ammonium formate, pH 3.00 adjusted with formic acid (75:25,
v/v). The ﬂow rate of the mobile phase was kept at 0.4 mL/min.
The sample manager temperature was maintained at 5 1C.
Ionization and detection of MPA and IS was carried out on a
Quattro Premier XETM mass spectrometer from Waters – Micro
Mass Technologies (MA, USA), equipped with turbo ion spray
interface and operated in positive ion mode. Quantitation was
performed using multiple reaction monitoring (MRM) mode to
monitor precursor-product ion transitions for MPA m/z 321.1-
207.0 and IS m/z 324.1-210.1. The source dependent parameters
maintained for MPA and IS were desolvation gas: 700 L/h;
capillary voltage: 3.5 kV; ion source temperature: 120 1C; deso-
lvation temperature: 300 1C; entrance potential: 1.0 V; and cone
gas ﬂow: 120 L/h. The optimum values for compound dependent
parameters like cone voltage and collision energy were 40 V and
14 eV respectively for MPA and IS. Quadrupole 1 and 3 were
maintained at unit mass resolution and the dwell time was set at
200 ms for both the drugs. Data collection, peak integration, and
calculations were performed using Mass Lynx software
version 4.1.
2.3. Calibrators and quality control samples
The standard stock solution of MPA (1000 mg/mL) was prepared
by dissolving accurately weighted amount in methanol. Calibration
standards (CSs) and quality control (QC) samples were prepared
by spiking blank plasma with stock solution. CSs were made at15.0, 30.0, 75.0, 150, 300, 750, 1500, 7500, 12000, and 15000 ng/
mL concentrations respectively, while QC samples were prepared
at 13000 ng/mL (HQC, high quality control), 6500/455 ng/mL
(MQC-1/2, middle quality control-1/2) and 40.0 ng/mL (LQC, low
quality control). Stock solution (1.0 mg/mL) of IS was prepared by
dissolving 25.0 mg in 25.0 mL of methanol. Its working solution
(1500 ng/mL) was prepared by appropriate dilution of the stock
solution in acetonitrile. Standard stock and working solutions used
were stored at 5 1C, while CSs and QC samples in plasma were
kept at −70 1C until use.
2.4. Sample preparation
Prior to analysis, all frozen subject samples, calibration standards
and quality control samples were thawed and allowed to equili-
brate at room temperature for 30 min. To an aliquot of 50 mL of
spiked plasma/subject samples, 250 mL of IS was added and
vortexed for about 2 min. The samples were centrifuged at
1431g for 10 min at 10 1C. Subsequently, 100 mL of supernatant
was transferred into pre-labeled tubes containing 100 mL of
10 mM ammonium formate solution. After brief vortex, 5 mL
was used for injection into the chromatographic system.
2.5. Method validation
System suitability experiment was performed by injecting six
consecutive injections using aqueous standard mixture of MPA
(6500 ng/mL) and IS (1500 ng/mL) at the start of each batch.
System performance was checked by injecting one extracted lower
limit of quantitation (LLOQ) sample with IS at the beginning of
each analytical batch and before re-injecting any batch during
method validation. Autosampler carryover was evaluated by
sequentially injecting extracted blank plasma-upper limit of
quantitation (ULOQ) sample-two extracted blank plasma sam-
ples-LLOQ sample-extracted blank plasma at the start and end
of each batch.
Selectivity of the method was assessed for potential matrix
interferences in ten batches (6 normal lots of K3EDTA, 2
haemolysed, and 2 lipemic) of blank human plasma by extraction
and inspection of the resulting chromatograms for interfering
peaks. Selectivity in the presence of MPAG was also evaluated
to check its impact on quantitation of MPA.
Five calibration lines containing ten non-zero concentrations
were used to determine linearity. A quadratic, 1/x2, least-squares
regression algorithm was used to plot the peak area ratio (analyte/
IS) from multiple reaction monitoring versus concentration. The
linear equations were then used to calculate the predicted
concentrations in all samples within the analytical runs. The
correlation coefﬁcient for each calibration curve must be ≥0.99
for both the analytes. The lowest standard on the calibration line
was accepted as the LLOQ, if the analyte response was at least ten
times more than that of extracted blank plasma. Reinjection
reproducibility for extracted samples was also checked by reinjec-
tion of an entire analytical run after storage at 5 1C.
Intra-batch accuracy and precision were evaluated by replicate
analysis of plasma samples on the same day. The analytical run
consisted of a calibration curve and six replicates of LLOQ, LQC,
MQC-1/2 and HQC samples. The inter-batch accuracy and
precision were assessed by analysis of ﬁve precision and accuracy
batches on three consecutive validation days. The precision
(% CV) at each concentration level from the nominal concentration
V. Upadhyay et al.208should not be greater than 15%. Similarly, the mean accuracy
should be within 85–115%, except for the LLOQ where it can be
within 80–120% of the nominal concentration [45].
Ion suppression/enhancement effects on the MRM LC–MS/MS
sensitivity were evaluated by post column analyte infusion
experiment as described previously [46]. Brieﬂy, a standard
solution containing MPA (at MQC-1 level) was infused post
column into the mobile phase at 10 mL/min employing infusion
pump. Aliquots of 5 mL of extracted control blank plasma sample
were then injected into the column by the autosampler and
chromatograms were acquired for the analyte and IS.
Extraction recovery of MPA and IS from human plasma was
evaluated in six replicates by comparing the mean peak area
responses of pre-extraction fortiﬁed samples to those of post-
extraction fortiﬁed samples representing 100% recovery. Matrix
effect, expressed as matrix factors (MFs) was assessed by
comparing the mean area response of post-extraction fortiﬁed
samples with mean area of solutions prepared in mobile phase
solutions (neat standards) at HQC, MQC-1/2 and LQC levels. To
evaluate the relative matrix effect in six plasma sources, pre-
extraction fortiﬁed samples were prepared in triplicate at LQC and
HQC concentration and assessed for accuracy (%) and precision
(% CV). In order to meet acceptance criteria for MF, the % CV
must be ≤15% and for relative matrix effect the accuracy should
not be more than 715% and % CV must be ≤15%. Further, at
least 90% of the lots at each QC level should be within the
aforementioned criteria.
Stock solutions of MPA and IS were checked for short term
stability at room temperature and long term stability at 5 1C.
Stability results in plasma were evaluated by measuring the area
ratio response (MPA/IS) of stability samples against freshly
prepared comparison standards with identical concentration. The
solutions were considered stable if the deviation from nominal
value was within 710.0%. Autosampler (wet extract at 5 1C),
bench top (at room temperature), freeze–thaw (at −20 1C and
−70 1C) and long term stability (at −20 1C and −70 1C) was
performed at LQC and HQC levels using six replicates. The
stability samples were quantiﬁed against freshly prepared quality
control samples. Stability data were acceptable if the % CV of the
replicate determinations did not exceed 15.0% and the mean
accuracy value was within 715.0% of the nominal value.
Method ruggedness was veriﬁed using two precision and
accuracy batches. The ﬁrst batch was analyzed on two different
columns of the same make but different batch number, while the
second batch was analyzed by two different analysts who were not
part of method validation. The ability to dilute samples which
could be above the upper limit of the calibration range was
validated by analyzing six replicate samples containing 27000 ng/
mL of MPA after two-/ten-fold dilution respectively. The precision
and accuracy for dilution reliability was determined by comparing
the samples against freshly prepared calibration curve standards.Fig. 1 Product ion mass spectra of (A) MPA (m/z 321.0-207.0) and
(B) internal standard, IS (m/z 324.1-210.1) in 100–420 amu scan range.2.6. Application of the method and incurred
sample reanalysis (ISR)
The aim of the study was to determine the bioequivalence of
500 mg MPM test (Generic Company, India) with a reference
(CellCepts, Roche Laboratories Inc. New Jersey, USA) tablet
formulation. The design was randomized, open label, balanced,
two-treatment, two-period, two-sequence, crossover study in 72
healthy adult Indian subjects under fasting. The primary targetvariables of the study were Cmax, AUC0–36, and AUC0–inf, which
were analyzed using the conﬁdence interval approach. The
secondary end points of the study included Tmax, Kel and t1/2.
The study was conducted as per the International Conference on
Harmonization, E6 Good Clinical Practice guidelines [47]. After
an overnight fasting, the subjects were orally administered a single
dose of test and reference formulations with 240 mL of water.
Blood samples were withdrawn at pre-dose time 0.00, 0.17, 0.25,
0.33, 0.42, 0.50, 0.58, 0.67, 0.83, 1.00, 1.17, 1.33, 1.50, 1.67,
1.83, 2.00, 2.17, 2.33, 2.50, 2.67, 2.83, 3.00, 3.25, 3.50, 3.75,
4.40, 4.33, 4.67, 5.00, 5.50, 6.0, 7.0, 8.0, 10.0, 12.0, 24.0 and
36.0 h and collected in labeled K3EDTA-vacuettes. After blood
collection, plasma separation was done by centrifugation at 1431g
for 10 min at 4 1C. The plasma samples were separated and
divided into two aliquots and stored in two different pre-labeled
radioimmunoassay (RIA) vials at −20 1C until analysis. The
statistical analysis for pharmacokinetic parameters of MPA
included descriptive statistics, analysis of variance and two one-
sided tests for bioequivalence using SASs software version 9.2
(SAS Institute Inc., Cary, NC, USA). To determine whether the
test and reference formulations were pharmacokinetically equiva-
lent, Cmax, AUC0–36 and AUC0–inf and their ratios (test/reference)
using log transformed data were assessed. The drug formulations
were considered pharmacokinetically equivalent if the difference
between the compared parameters was statistically non-signiﬁcant
(P≥0.05) and the 90% conﬁdence intervals (CI) for these para-
meters were within 80–125%.
Fig. 2 MRM ion-chromatograms of (A) mobile phase, (B) aqueous standard of MPA (15000 ng/mL), (C) aqueous standard of MPAG (15000 ng/mL),
(D) MPA (15000 ng/mL) spiked with MPAG (15000 ng/mL) before ﬁne tuning, (E) MPA (15000 ng/mL) spiked with MPAG (15000 ng/mL) after ﬁne
tuning of mass parameters and (F) MPA and MPAG in subject sample at 2.0 h after administration of 500 mg MPM. Optimized mass parameters before
and after ﬁne tuning were cone voltage: 45/40 V, desolvation temperature: 400/300 1C and cone gas ﬂow: 150/120 L/h respectively.
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V. Upadhyay et al.210An ISR for assay reproducibility was also done by reanalysis of
317 samples, which were near the Cmax and the elimination phase
in the pharmacokinetic proﬁle of the drug. The results were
compared with initial pharmacokinetic study using the same
procedure. As per the acceptance criterion at least two-thirds of
the original and repeat results should be within 20% of each other
[48].3. Results and discussion
3.1. Method development
Due to in-source conversion of MPAG metabolite to MPA it is
essential to separate both the analytes chromatographically. Back
conversion of this unstable metabolite to MPA must be considered
during sample preparation and subsequent analysis especially for
subject samples. In the present work, UPLC–MS/MS analysis was
done in the positive ionization mode to attain high sensitivity and a
good linearity in regression curves. The Q1 MS full scan spectra
for MPA and IS predominantly contained protonated precursor [M
+H]+ ions at m/z 321.0 and 324.1 respectively. The most abundant
and consistent product ions in Q3 MS spectra for MPA and ISFig. 3 Fine tuning of mass parameters (A) cone voltage, (B) desolvation t
MPAG to MPA.were found at m/z 207.0 and 210.1 respectively at 14 eV collision
energy (Fig. 1). Unlike previous report [36], maximum sensitivity
for quantitation purpose was achieved using the protonated
molecular ions instead of MPA ammonium ion adducts [MPA
+NH4
+] having m/z 338. In another report, in-source fragmentation
of MPAG was detected by measuring [MPA+H+] and not with
[MPA+NH4
+] as the precursor ion [42]. The MPA peak resulting
from in-source fragmentation of MPAG was seen well before the
original MPA peak when [MPA+H+] was measured from a patient
sample under treatment of MPM. MPAG undergoes in-source
fragmentation to MPA via loss of the glucuronic acid moiety
which can lead to overestimation of MPA concentration and could
be a major problem when both co-elute [41]. Thus it was
imperative to minimize the interference of MPAG for accurate
quantitation of MPA, as [MPA+H+] ions were studied in the
present work. Initially chromatographic trails were taken to ensure
an acceptable separation between MPA and MPAG and to avoid
any false concentration during subject sample analysis (Fig. 2A–
F). In-source fragmentation of MPAG to MPA was observed in
our study with aqueous standard of MPAG (15000 ng/mL) and
also when MPA aqueous sample (at ULOQ) spiked with MPAG
(15000 ng/mL) was injected (Fig. 2C and D). In the MRM
window of MPA an additional peak was observed at 1.11 minemperature and (C) cone gas ﬂow to minimize in-source conversion of
UPLC–MS/MS determination of mycophenolic acid in human plasma 211which was well resolved from MPA peak and did not contribute
to its peak area. Furthermore, to reduce in-source fragmentation,
cone voltage, desolvation temperature and cone gas ﬂow were
ﬁne tuned without compromising MPA response. Signiﬁcant
reduction in conversion was possible by maintaining the
desolvation temperature at 300 1C, cone voltage 40 V and cone
gas 120 L/h (Fig. 2E). Noticeably there was no signiﬁcant
conversion during subject sample analysis after optimization
of mass conditions (Fig. 2F). The effects of ion sourceFig. 4 Representative MRM ion-chromatograms of (A) double blank bloo
and IS, and (D) subject sample at 2.0 h after administration of 500 mg dotemperature, cone voltage and cone gas ﬂow on MPAG in-
source conversion are presented in Fig. 3. A dwell time of
200 ms for MPA and IS was adequate and no cross talk was
observed between their MRMs.
Different combinations of methanol/acetonitrile with acidic
buffers (formic acid/acetic acid-ammonium formate/ammonium
acetate) in different volume ratios were tested. Better separation,
higher sensitivity, efﬁciency and symmetric peak shapes were
obtained with acetonitrile: 10 mM ammonium formate, pH 3.0d (without MPA and IS), (B) blank plasma with IS, (C) MPA at LLOQ
se of MPM.
Table 2 Extraction recovery and matrix factors for mycophenolic acid and mycophenolic acid-d3.
Chemical QC level Area response Extraction recovery (B/A) (%) Matrix factor (A/C)
A B C
Mycophenolic acid HQC 473124 478372 464086 101.1 1.02
MQC-1 228384 223792 232486 97.9 0.98
MQC-2 16092 15574 16175 96.8 0.99
LQC 1395 1362 1428 97.6 0.97
Mycophenolic acid-d3 HQC 222575 217678 220371 97.8 1.01
MQC-1 218966 213054 214673 97.3 1.02
MQC-2 209917 201101 207839 95.8 1.01
LQC 214792 205341 219175 95.6 0.98
A: Mean area response of six replicates prepared by spiking in extracted blank plasma.
B: Mean area response of six replicates prepared by spiking before extraction.
C: Mean area response of six replicates prepared by spiking in mobile phase (neat samples).
Fig. 5 Injection of extracted blank human plasma during post column infusion of (A) MPA and (B) IS at MQC-1 level.
Table 3 Relative matrix effect in six different lots of human plasma for mycophenolic acid at HQC and LQC levels.
Plasma lots Observed concentration (ng/mL)
LQC (40.0 ng/mL)a HQC (13000 ng/mL)a
1 2 3 1 2 3
1 38.4 40.4 39.2 12667 12775 12636
2 39.9 39.2 39.1 12727 12829 12697
3 39.6 39.8 40.5 12587 12701 12573
4 40.1 40.9 40.3 12668 12879 12665
5 38.6 37.7 38.7 12593 12353 12967
6 37.6 37.9 37.5 11692 11985 11943
Mean (ng/mL) 39.2 12552
Standard deviation 0.95 273.6
Coefﬁcient of variation (%) 2.42 2.18
Accuracy (%) 97.9 96.6
aThree replicates for the same concentration.
V. Upadhyay et al.212(75:25, v/v) as the mobile phase. Under these conditions, retention
times of 1.21, 1.57 and 1.56 min were achieved for MPAG, MPA
and IS respectively with a run time of 2.0 min. The reproducibility
of retention times for MPA, expressed as % CV was ≤0.34% for
100 injections on the same column. Unlike the previous methods
that have employed a general internal standard [33,36,39,42], a
deuterated analog was used in the present work. MPA-d3
adequately compensated for any variability during extraction and
UPLC–MS/MS analysis. Sample preparation by protein precipita-
tion afforded clean chromatograms with no interfering peaks asevident from representative MRM ion chromatograms of extracted
blank plasma (without MPA and IS), blank plasma fortiﬁed with
IS, MPA at LLOQ and an actual plasma sample at 2.0 h (Fig. 4).
The mean extraction recovery across QC levels for MPA and IS
was 98.4% and 96.6% respectively (Table 2). The post column
infusion experiment conﬁrmed the absence of signal suppression
or enhancement at the retention time of MPA and IS (Fig. 5).
Noticeably an ion-suppression/enhancement was observed at 0.4–
0.6 min; however, it did not interfere in the quantitation of the
analyte.
UPLC–MS/MS determination of mycophenolic acid in human plasma 213Presence of unmonitored, co-eluting compounds from the matrix
can directly impact the accuracy, precision, ruggedness and overall
reliability of a validated method. Thus, it is recommended that
evaluation of matrix factors can help to assess the matrix effect. In
the present work, the matrix factor ranged from 0.97 to 1.02 for MPA
and IS (Table 2). The effect of different plasma sources on analyte
quantitation, expressed as relative matrix effect was established in four
normal K3EDTA, 1 haemolysed and 1 lipemic plasma sources. The %
CV values ranged from 2.18 to 2.42 and the accuracy was within
96.6–97.9% (Table 3), which is well within the acceptance criteria.
3.2. UPLC–MS/MS assay results
The precision (% CV) of system suitability test was observed in
the range of 0.05–0.11% for the retention time and 1.63–2.53% forTable 5 Stability of mycophenolic acid under different conditions in
Storage conditions Nominal concentration
Bench top stability at room temperature, 9 h 13000
40.0
Freeze–thaw stability after 5th cycle at −20 1C 13000
40.0
Freeze–thaw stability after 5th cycle at −70 1C 13000
40.0
Wet extract stability at 4 1C; 36 h 13000
40.0
Long term stability at −20 1C; 93 days 13000
40.0
Long term stability at −70 1C; 93 days 13000
40.0
Change ð%Þ ¼ Mean stability samples – Mean comparison samplesMean comparison samples  100
Fig. 6 Mean plasma concentration-time proﬁle of MPA after oral admin
healthy subjects under fasting conditions.
Table 4 Intra-batch and inter-batch accuracy and precision for myco
QC level (Nominal
concentration in ng/mL)
Intra-batch (n¼6; single batch)
Mean conc. found
(ng/mL)
CV
(%)
Accur
(%)
HQC (13000) 12216 2.8 93.9
MQC-1 (6500) 6003 1.7 92.4
MQC-2 (455) 454 5.9 99.8
LQC (40.0) 41.5 6.3 103.7
LLOQ QC (15.0) 14.6 6.7 97.3the area response for MPA and IS. The signal to noise ratio for
system performance was≥70 for analyte and IS. Carryover
evaluation showed minimal carryover (≤2.64% of LLOQ area)
in extracted blank plasma after succeeding injection of highest
calibration standard at the retention time of analyte and IS.
Five MPA calibration curves were linear over the concentration
range of 15–15000 ng/mL with a correlation coefﬁcient
(r2)≥0.9995. The mean linear equation obtained for MPA was
y¼ (0.9983870.00074)x+(0.0083670.00002). The accuracy and
precision (% CV) for the calibration curve standards ranged from
98.8% to 102.8% and 1.67% to 6.53%. The LLOQ (S/N≥70) and
limit of detection (LOD, S/N≥10) were 15 ng/mL and 2.5 ng/mL
respectively.
The intra-batch and inter-batch precision and accuracy for MPA
were established from validation runs performed at ﬁve QC levelshuman plasma (n¼6).
(ng/mL) Mean stability sample (ng/mL)7SD Change (%)
128397930 −1.3
39.274.8 −2.0
131397345 1.1
39.172.9 −2.3
128357314 −1.3
39.272.9 −2.0
124647280 −4.1
42.574.3 6.3
126077189 −3.0
38.671.2 −3.5
124897404 −3.9
37.970.6 −5.3
istration of 500 mg MPM test and reference tablet formulations to 72
phenolic acid.
Inter-batch (n¼30; 6 from each batch)
acy Mean conc. found for
5 batches (ng/mL)
CV
(%)
Accuracy
(%)
12706 4.7 97.7
6431 5.9 98.9
453 6.2 99.5
40.2 6.9 100.5
14.8 7.2 98.6
V. Upadhyay et al.214(Table 4). The intra-batch precision (% CV) ranged from 1.7 to 6.7
and the accuracy was within 92.4–103.7%. For inter-batch
experiment, the precision varied from 4.7% to 7.2% and the
accuracy was within 97.7–100.5%.
Stock solutions of MPA and IS for short term at room
temperature and long term at 573 1C were stable at room
temperature up to 8 h and for minimum period of 40 days
respectively. MPA in control human plasma (bench top) at room
temperature was stable for at least 9 h at 25 1C and for minimum
of ﬁve freeze–thaw cycles. Wet extract stability of the extracted
quality control samples was determined up to 36 h without
signiﬁcant loss of MPA. Long term stability of the spiked quality
control samples was unaffected up to minimum 93 days. The
detailed results for stability experiments are presented in Table 5.
The precision (% CV) and accuracy for method ruggedness
with different columns ranged from 2.9% to 3.7% and 94.5% to
97.4% respectively across ﬁve quality control levels. For the
experiment with different analysts, the results for precision and
accuracy were within 1.7–3.2% and 96.1–100.6% respectively at
these levels. The precision (% CV) for dilution reliability of 1/2
and 1/10th dilution was between 2.3% and 3.3% respectively,
while the accuracy results were within 95.8–96.8%, which is
within the acceptance limit of 15% for precision (% CV) and 85–
115% for accuracy.Fig. 7 % Change for assay reproducibility results with 317 incurred
study samples.3.3. Application to bioequivalence study and ISR results
The developed method was used to estimate MPA concentration in
human samples after administration of 500 mg oral dose of MPM.
Fig. 6 shows the mean plasma concentration vs. time proﬁle of
MPA in healthy subjects. The method was sensitive enough to
monitor MPA concentration up to 36.0 h. The mean pharmacoki-
netic parameters and log transformed geometric least squares mean
values for AUC0–36, AUC0–inf and Cmax under fasting conditions
are summarized in Table 6. The results obtained can be compared
with a similar study with identical MPM dose strength in healthy
Indian subjects [39]. The mean Cmax, AUC0–36 and AUC0–inf
values were a bit lower in the present work, albeit with much less
variation. However, t1/2 and Kel values were comparable with that
study. The 90% conﬁdence interval of individual ratio geometric
mean for test/reference was within 80–125%, which corroborates
bioequivalence of the test sample with the reference product in
terms of rate and extent of absorption. Furthermore, there was no
adverse event during the course of the study.
ISR results showed % change for assay reproducibility within
5% for 155 samples, 5–10% for 73 samples, 10–15% for 60
samples, while the remaining 29 samples showed % changeTable 6 Mean pharmacokinetic parameters (7SD) and 90% C
administration of 500 mg test and reference formulations of mycophen
Parameter Test Reference Ratio (te
(%)
Cmax (ng/mL) 1127174298 1075273599 103.4
AUC 0–36 (h ng/mL) 2359074921 2391075086 99.3
AUC 0–inf (h ng/mL) 2624876363 2653277175 99.7
Tmax (h) 1.8170.73 1.8470.79 —
t1/2 (h) 11.7675.84 10.9775.47 —
Kel (1/h) 0.07270.025 0.07870.023 —between 15% and 20% (Fig. 7). This authenticates the reprodu-
cibility of the proposed method.
3.4. Comparison with reported procedures
The proposed method is more sensitive compared to all other
methods developed for estimation of total MPA concentration in
plasma and rapid compared to several HPLC [18–29] and LC–MS/
MS [31,33,35,36,39] methods in biological samples. The present
method employed only 50 mL plasma volume for processing,
which is low compared to several methods [31,33,35,36,39] and
identical with few others [38,43]. Only three other methods
employ volumes less than 50 mL [37,40,42]. Additionally, the
on-column loading of MPA is 16 ng per injection at ULOQ level,
which is much less compared to previous reports
[31,33,35,36,38,39,43]. Further, assay reproducibility is compre-
hensively demonstrated by incurred sample reanalysis, which is
not reported in methods employing mass spectrometric detection
[30–43].4. Conclusions
The UPLC–MS/MS method for the quantitation of MPA in human
plasma was developed and fully validated as per the USFDA
guidelines. A total of approximately 9500 samples were analyzed
during a period of 12 days, which included calibration, QC andIs of natural log (Ln)-transformed parameters following oral
olic acid in 72 healthy Indian subjects.
st/reference) 90% conﬁdence interval
(Lower–Upper)
Intra-subject variation
(% CV)
98.3–108.8 5.25
95.7–102.9 5.17
94.9–104.7 6.34
— —
— —
— —
UPLC–MS/MS determination of mycophenolic acid in human plasma 215subject samples and the precision and accuracy were well within
the acceptable limits. The advantages of this method include high
sensitivity, small sample volume for processing, and short
chromatographic run time. The efﬁciency of protein precipitation
and a chromatographic run time of 2.0 min per sample make it an
attractive procedure in high-throughput clinical analysis of MPA.
Based on dilution reliability results it is possible to extend the
ULOQ to 27000 ng/mL. In addition, assay reproducibility is
effectively proved by reanalysis of 317 subject samples.
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